Increased Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis

Pehlevan, Seval; Yetkin, Demet Özgil; Bahadır, Cengiz; Göktay, Fatıh; Pehlevan, Yekta; Kayataş, Kadir; İnce, Nurhan

doi:10.1089/met.2013.0039

Cited by 33 publications

(36 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A limited number of previous studies have indicated that the prevalence of MetS in patients with PsA is between 23.5% and 58.1% (21)(22)(23)(24). There is one study that investigated the prevalance of MetS in a small number of patients with PsA in Turkey (9). The authors of that study reported that the prevalance of MetS in patients with PsA using NCEP criteria was 40.6%, which was similar to our results.…”

Section: Discussionsupporting

confidence: 90%

“…Studies on the prevalence of MetS in Turkey ranges from 26.5% to 42.6% (6)(7)(8). Recent studies have shown that the prevalence of MetS and cardiovascular diseases (CVDs) increases in patients with PsA and that CVDs are the most common cause of death in patients with PsA (9)(10)(11)(12)(13)(14). The aim of this study was to identify the prevalence of MetS and the degree of CVD risk in patients with PsA compared to patients with RA in a Turkish population.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Yazısız

Behlül

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

Objective: The aim of this study was to identify the prevalence of metabolic syndrome (MetS) and degree of cardiovascular disease (CVD) risk in patients with psoriatic arthritis (PsA). Material and Methods:We performed a cross-sectional study on 102 adult patients with PsA and a control group of 102 patients with rheumatoid arthritis (RA). MetS was diagnosed according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP-ATP III) and International Diabetes Federation (IDF) criteria. The Framingham risk scores of 10-year risk of CVDs and coronary heart disease (CHD) were also calculated.Results: The prevalence of MetS was higher in patients with PsA than in those with RA, according to the NCEP-ATP III (40.6% vs.24.7%, respectively; p=0.019) and IDF (46.8% vs. 27.9%, respectively; p=0.05) criteria. The prevalence of MetS was higher in female patients with PsA (p=0.009) than in male patients. A significantly increased prevalence of hypertriglyceridemia was determined in patients with PsA (p=0.019). No significant difference existed between the two groups with respect to 10-year CVD (p=0.333) and CHD (p=0.798) risks. Additionally, there were no significant differences between the clinical subtypes of PsA with regard to MetS (p=0.229). Conclusion:MetS prevalence increased in patients with PsA compared with those with RA, whereas the risks were similar for CVDs and CHD. For this reason, optimal protection measures should be taken and guidelines should be applied to achieve adequate metabolic control in patients with PsA.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Introductionmentioning

confidence: 99%

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Yazısız

Behlül

et al. 2017

Eur J Rheumatol

View full text Add to dashboard Cite

show abstract

“…However, after restricting the analysis to those without IBD, AS or RA, the findings remained substantially unchanged. An association between obesity, including the metabolic syndrome, and PsA is well established . In our cohort, a greater proportion of pregnancies with PsA were complicated by obesity than non‐PsA pregnancies but the frequency of pre‐pregnancy hypertension was low.…”

Section: Discussionmentioning

confidence: 66%

Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study

Remaeus

Stephansson

Johansson

et al. 2019

BJOG

View full text Add to dashboard Cite

Objective Studies on pregnancy outcomes in psoriatic arthritis (PsA) are scarce and typically of small size. Available studies have reported conflicting results. The aim of this study was to describe maternal and infant pregnancy outcomes among women with PsA compared with women without PsA.Design Nationwide cohort study.Setting Nationwide Swedish registers.Population A total of 41 485 singleton pregnancies in 1997-2014, of which 541 pregnancies were identified with PsA exposure and 40 944 pregnancies were unexposed.Methods By linkage of national health and population register data, we obtained information on individual pregnancies and compared outcomes among pregnancies with PsA and non-PsA pregnancies. Relative risks were estimated by odds ratios (ORs) with 95% CIs using a generalised linear regression model with generalised estimating equations. Adjustments were made for maternal factors and calendar year of birth. Main outcome measures Maternal and infant pregnancy outcomes.Results Pregnancies to women with PsA had increased risks of preterm birth (adjusted OR 1.63; 95% CI 1.17-2.28), elective and emergency caesarean deliveries (adjusted OR 1.47; 95% CI 1.10-1.97 and adjusted OR 1.43; 95% CI 1.08-1.88, respectively) compared with non-PsA pregnancies. No increased risks were observed for pre-eclampsia, stillbirth or other infant outcomes apart from preterm birth. ConclusionThe majority of women with PsA have uneventful pregnancies with respect to adverse outcomes. In the present study, we found increased risks of preterm birth and caesarean delivery compared with non-PsA pregnancies.Keywords Pregnancy outcome, preterm birth, psoriatic arthritis.Tweetable abstract Women with psoriatic arthritis have uneventful pregnancies but are at increased risk of preterm birth and caesarean delivery.

show abstract

“…This screening must be performed annually in patients receiving topical treatment for their psoriasis and every 6 months in patients on systemic treatments. psoriasis have an increased prevalence of metabolic syndrome, with a positive relationship with the severity of psoriasis(120)(121)(122). To detect the existence of this condition, clinicians must assess the presence of three or more of the following criteria defined by the National Cholesterol Education Program (ATP III) (119): abdominal obesity; tryglicerides >150 mg/dL or specific treatment; HDL-C <40 mg/dL in men or <50 mg/dL in women or specific treatment; BP >130/85 mm/Hg or treatment for hypertension; fasting glucose >100 mg/dL.…”

mentioning

confidence: 99%

Measuring psoriatic disease in clinical practice. An expert opinion position paper

Lubrano

Cantini

Costanzo

et al. 2015

Autoimmunity Reviews

View full text Add to dashboard Cite

Increased Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis

Cited by 33 publications

References 22 publications

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Prevalence of metabolic syndrome and degree of cardiovascular disease risk in patients with Psoriatic Arthritis

Maternal and infant pregnancy outcomes in women with psoriatic arthritis: a Swedish nationwide cohort study

Measuring psoriatic disease in clinical practice. An expert opinion position paper

Contact Info

Product

Resources

About